MANGOCEUTICALS INC
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
MGRX$0.19+1.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
Mangoceuticals, Inc. and Subsidiary
Condensed Consolidated Balance Sheets
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| (Unaudited) | (Audited) | |
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $73,912 | $739,006 |
| Inventory | 13,213 | 18,501 |
| Prepaid expenses - related party | - | 60,953 |
| Deposits | 16,942 | 16,942 |
| TOTAL CURRENT ASSETS | 104,067 | 835,402 |
| NON-CURRENT ASSETS | ||
| Property and equipment, net of accumulated depreciation of $2,001 and $28,752 | 3,061 | 96,129 |
| Right of use - asset | 74,913 | 119,262 |
| Intangible assets - acquired patents | 14,610,000 | - |
| TOTAL NON-CURRENT ASSETS | 14,687,974 | 215,391 |
| TOTAL ASSETS | $14,792,041 | $1,050,793 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued liabilities | 707,519 | 140,765 |
| Accounts payable and accrued liabilities - related party | 46,443 | - |
| Payroll tax liabilities | 5,580 | 6,595 |
| Notes payable to related parties | 187,500 | - |
| Right-of-use liability - operating lease | 69,340 | 63,718 |
| Other liabilities - patent purchase payable | 375,000 | - |
| TOTAL CURRENT LIABILITIES | 1,391,382 | 211,078 |
| LONG-TERM LIABILITIES | ||
| Right-of-use liability - operating lease | 12,167 | 64,961 |
| TOTAL LONG-TERM LIABILITIES | 12,167 | 64,961 |
| TOTAL LIABILITIES | 1,403,549 | 276,039 |
| COMMITMENTS AND CONTINGENCIES (SEE NOTE 11) | - | - |
| STOCKHOLDERS’ EQUITY | ||
| Series B Convertible Preferred stock, (par value $0.0001), 6,000 shares authorized, 1,860 and 0 shares were issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | - | - |
| Series C Convertible Preferred stock (par value $0.0001), 6,250,000 shares authorized) 980,000 and 0 shares were issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 98 | - |
| Common stock (par value $0.0001), 200,000,000 shares authorized, 2,134,625 and 1,427,967 were issued and outstanding as of September 30, 2024 and December 31, 2023, respectively* | 213 | 148 |
| Stock warrants | 34,300 | - |
| Subscription receivable | (250,000) | - |
| Additional paid in capital | 31,592,347 | 12,002,779 |
| Accumulated deficit | (17,985,966) | (11,228,173) |
| Accumulated other comprehensive loss | (1,663) | - |
| TOTAL STOCKHOLDERS’ EQUITY | 13,389,329 | 774,754 |
| Non-controlling interest | (837) | - |
| TOTAL STOCKHOLDERS’ EQUITY | 13,388,492 | 774,754 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $14,792,041 | $1,050,793 |
| * | Shares have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 15 reverse stock split |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.